MENU
+Compare
ATNM
Stock ticker: ASE
AS OF
Sep 12 closing price
Price
$1.63
Change
-$0.05 (-2.98%)
Capitalization
50.85M

ATNM Actinium Pharmaceuticals Forecast, Technical & Fundamental Analysis

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options... Show more

Industry: #Biotechnology
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ATNM with price predictions
Sep 12, 2025

ATNM in upward trend: 10-day moving average crossed above 50-day moving average on August 19, 2025

The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on August 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where ATNM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

ATNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 05, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

ATNM moved below its 50-day moving average on September 12, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ATNM entered a downward trend on August 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.675) is normal, around the industry mean (20.731). P/E Ratio (0.000) is within average values for comparable stocks, (53.474). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.171). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (337.655).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ATNM is expected to report earnings to rise 44.32% to -31 cents per share on November 24

Actinium Pharmaceuticals ATNM Stock Earnings Reports
Q3'25
Est.
$-0.32
Q2'25
Beat
by $0.13
Q1'25
Missed
by $0.13
Q4'24
Beat
by $0.16
Q3'24
Est.
$-0.37
The last earnings report on July 28 showed earnings per share of -21 cents, beating the estimate of -34 cents. With 102.75K shares outstanding, the current market capitalization sits at 50.85M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
100 Park Avenue
Phone
+1 646 677-3870
Employees
49
Web
https://www.actiniumpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLNE2.500.08
+3.31%
Beeline Holdings Inc
AYALY11.01N/A
N/A
Ayala Corp.
DRDGF2.09N/A
N/A
DRDGOLD Ltd.
RSDEF2.39N/A
N/A
Ramsdens Holdings PLC
AAQL0.60-0.12
-16.66%
Antiaging Quantum Living Inc.

ATNM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with CRBU. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
-2.98%
CRBU - ATNM
45%
Loosely correlated
-5.76%
IPSC - ATNM
45%
Loosely correlated
-3.38%
RXRX - ATNM
42%
Loosely correlated
-0.41%
HLVX - ATNM
40%
Loosely correlated
N/A
PRME - ATNM
40%
Loosely correlated
-0.25%
More